Applied Symbiotic Intelligence
Buy Better Intelligence
A new form of advanced research for bespoke discovery in Life Sciences R&D.
Better intelligence reduces R&D risk
Discipline is what turns intelligence into discovery.
How ASI works
Case studies
ASI's deliverable ranked above frontier-AI defaults on a dengue-vaccine safety questionOn the same scientific input, ASI's proprietary methodology was independently ranked #1 on R&D-risk reduction.Read the case study →ASI surfaced testable checkpoint-combination predictions for an immuno-oncology trial — from published literature aloneNo new wet-lab data needed. Cross-paper synthesis with full citation provenance.Request the brief →ASI mapped cross-lab synergies inside one institution's own gene-therapy work — with $8-23M cost-avoidance implicationsEight published papers, one synthesis. Five actionable findings. Two carry late-discovery cost ranges.Request the brief →ASI surfaced six years of unpublished pharmacology direction from one paper — in 36 hoursThe lead author had pursued this direction privately for six years. The methodology surfaced it from her own published work.Request the brief →
Different verb
We discover. Others predict, retrieve, answer, execute.
Every AI in life sciences operates on a verb. Our verb is upstream of theirs — every other AI sits downstream of the decisions our methodology surfaces.
Company
Verb
What it does
ASI
discovers
Cross-paper hypothesis generation with full provenance and adversarial stress-test
AlphaFold 3
predicts
Protein structure from amino-acid sequence
Causaly
retrieves
Biomedical knowledge-graph search across published literature
OpenEvidence
answers
Clinical Q&A grounded in peer-reviewed evidence
Claude / Gemini agents
executes
General-purpose AI task automation across arbitrary domains
The verb determines the layer. Discovery is upstream of prediction, retrieval, answers, and execution — each of those operates on hypotheses that someone, somewhere, surfaced first.
Domain-expert validation
The validators are the substrate-paper authors of the work we analyze. Their endorsement is the methodology test that matters.
Pharmacology & Translational · Major Research University
Reviewed our 36-hour analysis of one of the team's own papers. The methodology surfaced the scientific directions the lab had pursued for six years in unpublished research.
36 hours to match 6 years of unpublished direction.
Immuno-Oncology · Major Research University
Reviewed our analysis of seven-year-old published research by the team — the people on Earth best positioned to judge accuracy.
37 min to first response → co-author in 48 hrs → publication pipeline in 3 days.
Veterinary Oncology · Major Research University
Reviewed cross-species findings. Championed the work across disciplines; connected us to collaborators at multiple institutions.
Work propagated on the reviewer's initiative.
Methodology track record
7
Patents-pending
12+
Scientific domains validated
#1
Independently ranked above frontier-AI defaults
Zero
External funding to date
How to start
1
Self-ServeUpload a manuscript or research input. One transparent price based on expected tokens for a full Discovery (DADE) run. Optional Healing (DAHE) add-on at the same base price — add now or come back later.Hours, not weeks · one quote, one number · full citation provenance · you own the output outright
2
PilotScoped paid deliverable on a manuscript, hypothesis, or single asset.1–2 weeks · findings + evidence chains + identified opportunities
3
ProjectCross-domain analysis on a therapeutic area, pipeline asset, or strategic question.2–4 weeks · full intelligence package with testable hypotheses
4
ProgramRecurring intelligence cadence; cross-portfolio visibility; methodology compounds.Ongoing · priority analysis pipeline · direct analytical access
Essays
Long-form pieces on what discipline looks like when you point it at scientific discovery.
References
Every claim on this page traces to a primary source. Quantitative claims are field-verified per the ASI Source-Integrity Gate; case-study corpus citations are PubMed-indexed where applicable.
- IQVIA Institute, Global Trends in R&D 2025 (March 2025) — top-20 pharma R&D spend reached $190B in 2024 (+16.6% YoY). — Primary source↑
- Citeline Biomedtracker / BIO, Clinical Development Success Rates 2014–2023 (2024) — 6.7% Phase I → approval likelihood, down from 10.4% a decade earlier. — Industry-attested↑
- Borah R, Brown AW, Capers PL, Kaiser KA. Analysis of the time and workers needed to conduct systematic reviews of medical interventions using data from the PROSPERO registry. BMJ Open 2017;7(2):e012545. — PubMed · PMID 28242767↑
- Michelson M, Reuter K. The significant cost of systematic reviews and meta-analyses: A call for greater involvement of machine learning to assess the promise of clinical trials. Contemp Clin Trials Commun 2019;16:100443. — PubMed · PMID 31497675↑
- Deloitte, Measuring the Return from Pharmaceutical Innovation 2025 — 15th edition, "Be brave, be bold" (March 2025) — top-20 cohort wrote off $7.7B on terminated clinical trials in 2024. — Primary source↑
Get started with ASI
Your published papers already contain breakthroughs nobody has connected. Discipline is how we find them — every claim traced to source, every hypothesis stress-tested before you see it.